Drugs / Tumor-draining lymph node-derived lymphocyte (LNL)
Tumor-draining lymph node-derived lymphocyte (LNL)
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06121570 | Nov 2023 → Aug 2026 overdue | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1 | NCT06121557 | Nov 2023 → Dec 2026 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05981001 | Aug 2023 → Apr 2032 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor-draining lymph node-derived lymphocyte (LNL) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06121570 ↗ |